There is currently no approved vaccine for Shigella spp., a leading cause of diarrhea with increasing rates of antimicrobial resistance. Shigella vaccine development is complicated in part by an incomplete understanding of the structural and molecular determinants of immunity. To address this, we isolated monoclonal an...
Robert M. Gallant, Paul Savarino, Sophia Pulido et al.· Science Translational Medici...· 0 citations
AlphaFold is used to generate a model of the upper portion of the Shigella pod complex in which two copies of the SctQ protein, Spa33, bind the adaptor protein MxiK, with each copy of Spa33 bound to an alternately translated SPOA2-SPOA2 domain, albeit in a manner that places the protein components slightly closer to th...
Sean K. Whittier, Shoichi Tachiyama, Samira Heydari et al.· PLoS Pathogens· 0 citations
ABSTRACT Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) are ESKAPE pathogens that are responsible for severe skin and soft tissue infections (SSTIs), particularly in the elderly and those with immunocompromising conditions. Rising rates of methicillin-resistant S. aureus (MRSA) and carbapenem-resistant PA h...
Suhrid Maiti, T. Lu, Zackary Dietz et al.· Infection and Immunity· 0 citations
It is established that the vaccine formulation can effectively boost and redirect pre-existing immunity, offering a promising approach to overcome the limitations of natural exposure and protect at-risk individuals from diverse Pa infections.
D. R. Howlader, Sayan Das, Satabdi Biswas et al.· Infection and Immunity· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
